These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23945965)

  • 1. Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study.
    Shimamoto K; Hasebe N; Ito S; Kario K; Kimura K; Dohi Y; Kawano Y; Rakugi H; Horiuchi M; Imaizumi T; Ohya Y
    Hypertens Res; 2014 Jan; 37(1):69-75. PubMed ID: 23945965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension.
    Shimamoto K; Kimoto M; Matsuda Y; Asano K; Kajikawa M
    Hypertens Res; 2015 Oct; 38(10):695-700. PubMed ID: 25876832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group.
    Zidek W; Spiecker C; Knaup G; Steindl L; Breuer HW
    Clin Ther; 1995; 17(4):686-700. PubMed ID: 8565032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I; Saruta T;
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective controlled trial of two nifedipine extended release formulations in the treatment of essential hypertension.
    Pivac N; Naranca M; Vujic-Podlipec D; Bagatin J; Rumboldt Z
    Arzneimittelforschung; 2002; 52(5):379-84. PubMed ID: 12087923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised double-blind study comparing nifedipine GITS 20 mg and bendrofluazide 2.5 mg administered once daily in mild-to-moderate hypertension.
    Isles CG; Kitchin NR
    J Hum Hypertens; 1999 Jan; 13(1):69-73. PubMed ID: 9928755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, controlled, multicenter, randomized study comparing the antihypertensive effectiveness and tolerance of a daily dose of two nifedipine formulations: nifedipine microgranules versus nifedipine osmotic pump.
    de Roa ER; Botero R; Octavio JA; Berrizbeitia ML; Mayorca E; Castro P; Miranda R; Valecillo E; Aroca G; Aza G; González M
    Am J Ther; 2007; 14(2):140-6. PubMed ID: 17414581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily.
    Fujiwara T; Ii Y; Hatsuzawa J; Murase H; Watanabe T; Murakami M; Kimura N; Buch J; Tsuchihashi T; Saruta T
    J Hum Hypertens; 2009 Aug; 23(8):521-9. PubMed ID: 19148107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prazosin GITS vs sustained release nifedipine in patients with hypertension and abnormal lipid profile: a randomized, controlled, multicenter study. Madras Hypertension Study Group.
    Misra KP; Joglekar SJ; Mukherjee S; Nanivadekar AS
    J Assoc Physicians India; 1998; Suppl 1():30-40. PubMed ID: 11233385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure control in patients with mild to moderate essential hypertension switched from nifedipine gastrointestinal therapeutic system (GITS) 30 mg to nifedipine GITS 20 mg.
    Toal CB;
    Clin Ther; 2001 Jan; 23(1):87-96. PubMed ID: 11219482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses.
    Kjeldsen SE; Cha G; Villa G; Mancia G;
    J Clin Pharmacol; 2016 Sep; 56(9):1120-9. PubMed ID: 26829251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.
    Lefebvre J; Poirier L; Archambault F; Jewell D; Reed CV; Lacourcière Y
    Can J Cardiol; 1998 May; 14(5):682-8. PubMed ID: 9627524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisoprolol and nifedipine SR in the treatment of hypertension in the elderly.
    Oliván Martinez J; Garcia MJ; Rodriguez Botaro A; Pizarro JL; Carretero J; Garrido M
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S95-9. PubMed ID: 11527144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension.
    Fagan TC; Haggert BE; Liss C
    Clin Ther; 1994; 16(4):634-46. PubMed ID: 7982251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of lacidipine and nifedipine SR in the treatment of hypertension: an Italian multicenter study. The Northern Italian Study Group of Lacidipine in Hypertension.
    Leonetti G
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S31-4. PubMed ID: 1726003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.
    Fujikawa K; Hasebe N; Kikuchi K;
    Hypertens Res; 2005 Jul; 28(7):585-91. PubMed ID: 16335887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine.
    Welzel D; Burger KJ; Weidinger G
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S70-4. PubMed ID: 1695308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of two modified release preparations of nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily--in the treatment of mild to moderate hypertension.
    Kirby BJ; Kitchin NR
    Int J Clin Pract; 1999; 53(5):339-43. PubMed ID: 10695096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.